Pathological complete response was seen in 21.5% (n = 12/56) of patients with locally advanced HER2-positive gastric cancers following neoadjuvant combination therapy, exceeding the pre-specified threshold of 20% to warrant further investigation [95]. Here, ERBB2 is linked to gastric cancer.